Connect Biopharma is trading at $2.46, up 6.84% from its August 24, 2026 close of $2.30, possibly reflecting broader risk-on sentiment with the catalyst uncertain.
- No new company-specific announcement, earnings release, regulatory update, or analyst action was identified for August 25.
- The latest material update remains the August 12 quarterly report, which announced September topline data for two Phase 2 studies.
- Nasdaq futures are up 0.67%.